Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
Influenza A Viral Infections Drug Development Pipeline Review, 2018
Summary
This report provides an overview of the pipeline landscape for influenza A viral infections. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for influenza A H3N2, H1N1, H5N1 and H7N9 subtype infections, and features dormant and discontinued products.
Influenza is an acute infection of the respiratory tract that predominately affects the nose, throat and bronchi, and less commonly the lungs. Influenza viruses have a single-stranded segmented RNA genome. They belong to the family Orthomyxoviridae, and are categorized into three genera based on their core proteins – A, B and C. Influenza A and B viruses are responsible for the majority of symptomatic cases of influenza in humans.
Influenza A viruses can be further categorized based on their expression of two viral surface proteins: hemagglutinin (H); and neuraminidase (N). These viruses are known to have high mutation rates, with frequent changes to the viral protein structure.
Scope
- Which companies are the most active within the pipeline for influenza A viral infections?
- Which pharmaceutical approaches are most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened within this field?
Reasons to buy
- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
Summary
This report provides an overview of the pipeline landscape for influenza A viral infections. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for influenza A H3N2, H1N1, H5N1 and H7N9 subtype infections, and features dormant and discontinued products.
Influenza is an acute infection of the respiratory tract that predominately affects the nose, throat and bronchi, and less commonly the lungs. Influenza viruses have a single-stranded segmented RNA genome. They belong to the family Orthomyxoviridae, and are categorized into three genera based on their core proteins – A, B and C. Influenza A and B viruses are responsible for the majority of symptomatic cases of influenza in humans.
Influenza A viruses can be further categorized based on their expression of two viral surface proteins: hemagglutinin (H); and neuraminidase (N). These viruses are known to have high mutation rates, with frequent changes to the viral protein structure.
Scope
- Which companies are the most active within the pipeline for influenza A viral infections?
- Which pharmaceutical approaches are most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened within this field?
Reasons to buy
- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
